Skip to main content
LTRN logo

Lantern Pharma Inc. (LTRN) Stock Price & Analysis

Lantern Pharma Inc. (LTRN) — MoonshotScore 29/100 (Weak band), calculated Nov 18, 2026. Price $0.245 (-13.73%), as of the Nov 20, 2026 trading session; market cap $3.89M.

Educational signal · not a buy or sell recommendation · How to read this

$0.245 −$0.039 (-13.73%) Market Cap $3.89M

Lantern Pharma Inc. · LTRN · NASDAQ

Lantern Pharma Inc. is a clinical-stage biotechnology company that leverages artificial intelligence and machine learning to accelerate drug development.

Price as of Nov 20, 2026

Key Statistics

29 of 100

MoonshotScore v2 · Lantern Pharma (LTRN)

Weak
Business Quality Thin (22)
Financial Safety Fragile (13)
Valuation Full (46)
Growth Durability Fading (37)
Momentum Falling (13)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Bottom-tier quality, a fragile balance sheet, weak growth and a full valuation, and the price trend has turned against it. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone. Business Quality: Thin; Financial Safety: Fragile; Valuation: Full; Growth Durability: Fading; Momentum: Falling.

  • EPS beat 0 of the last 4 reports
  • Altman Z -23.73 · Piotroski F 1

Holding back: weak fundamentals, balance-sheet strain, weak price trend

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for LTRN (58 recorded, newest six shown)
RecordedScoreBand
27Weak
28Weak
28Weak
29Weak
29Weak
29Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$0.245
Change on the day-13.73%
Market capitalisation$3.89M—
Shares traded on the day234.2K

Price & events

Other perspectives

Council score for Lantern Pharma (LTRN): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Weak
Financial Safety Negative
Valuation Neutral
Growth Durability Weak
Momentum Negative

Legends Council

5 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Unfavorable read

Read on: Nov 19, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Undervalued
Profit Margin Weak
Debt/Equity Strong
ROE Negative
Gross Margin Negative

Read on: Nov 19, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Nov 19, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.

Readings on this page are from Nov 21, 2026, except a card that shows its own read date.

1 · What is it?

What is Lantern Pharma (LTRN), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Lantern Pharma Inc. (LTRN) is listed on NASDAQ. It employs 16 people. The market values it at $3.89M.

2 · Latest results

What do the latest results show for Lantern Pharma (LTRN)?

Short answer · as of

Against analyst estimates the company has EPS beat 0 of the last 4 reports.

3 · Financial strengths and risks

What are the financial strengths and risks for Lantern Pharma (LTRN)?

Short answer

What is holding it back is weak fundamentals, balance-sheet strain, weak price trend. The distress and quality screens read Altman Z -23.73 · Piotroski F 1. Trailing ratios: ROA -93.1% · current ratio 1.49.

Data-derived red flags

  • Listing risk — at $0.245 the shares sit below the $1.00 minimum bid NASDAQ requires for continued listing.
  • Financial-distress signal — its Altman Z-Score of -23.73 sits in the distress zone (elevated bankruptcy risk).
  • Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
4 · What to check next?

What should you watch next at Lantern Pharma (LTRN)?

Short answer · as of

Analyst estimates on file carry FY2026 revenue $1.95M · EPS -1.63 · 1 analysts.

What the records here don't tell us

  • The next earnings date is not yet scheduled in the calendar we read.
  • No quarterly income statement is held for LTRN.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Lantern Pharma compare with its peers?

Short answer

Lantern Pharma's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Fennec Pharmaceuticals Inc. (FENC) Same industry, near in market value$13.45 Nov 19, 2026$475M91 5-pillar Nov 18, 2026
Zevra Therapeutics, Inc. (ZVRA) Same industry, near in market value$9.07 Nov 19, 2026$540M91 5-pillar Nov 18, 2026
Protalix BioTherapeutics, Inc. (PLX) Same industry, near in market value$2.90 Nov 20, 2026$245M90 5-pillar Nov 18, 2026
Rigel Pharmaceuticals, Inc. (RIGL) Same industry, near in market value$41.19 Nov 19, 2026$776M88 5-pillar Nov 18, 2026
Rallybio Corporation (RLYB) Same industry, near in market value$15.52 Nov 19, 2026$86.9M82 5-pillar Nov 18, 2026
ImmuCell Corporation (ICCC) Same industry, near in market value$11.17 Nov 19, 2026$102M82 5-pillar Nov 18, 2026
Oramed Pharmaceuticals Inc. (ORMP) Same industry, near in market value$3.69 Nov 19, 2026$160M72 5-pillar Nov 18, 2026
Compugen Ltd. (CGEN) Same industry, near in market value$1.84 Nov 20, 2026$174M69 5-pillar Nov 18, 2026
Pharming Group N.V. (PHAR) Same industry, near in market value$11.54 Nov 20, 2026$817M69 5-pillar Nov 18, 2026
Climb Bio, Inc. (CLYM) Same industry, near in market value$9.28 Nov 19, 2026$545M68 5-pillar Nov 18, 2026
SpyGlass Pharma, Inc. Common Stock (SGP) Same industry, near in market value$30.43 Nov 20, 2026$1.02B64 5-pillar Nov 18, 2026
MeiraGTx Holdings plc (MGTX) Same industry, near in market value$7.98 Nov 20, 2026$780M63 5-pillar Nov 18, 2026
Lantern Pharma (LTRN) — this page$0.245$3.89M29

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Revenue estimate
$1.95M
EPS estimate
$-1.63

Measured against a quoted price of $0.245 (as of Nov 20, 2026).

Insider activity

Form 4 records via FMP · Most recent available transactions

Transactions
12
Identified insiders
4
Purchases
2
Sales
0
Other transactions
10

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held LTRN in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported LTRN in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Lantern Pharma (LTRN)?

Read these with our analysis →

Common Questions About LTRN

These answers are editorial: 1 of these 9 answers is drawn from the LTRN research dossier (written May 10, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for LTRN?

LTRN carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.

Is LTRN a good stock to buy?

Stock Expert AI does not rate LTRN buy, sell or hold. Lantern Pharma Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the LTRN stock price today?

The last price recorded for Lantern Pharma Inc. (LTRN), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What do analysts say about LTRN stock?

Analyst coverage of Lantern Pharma Inc. is limited, reflecting its small market capitalization and early stage of development. However, analysts generally view the company's AI-driven approach to drug discovery as a potential differentiator in the competitive biotechnology landscape.

What are the key factors to evaluate for LTRN?

Lantern Pharma Inc. (LTRN) holds a MoonshotScore in the low range. The RADR AI platform analyzes molecular data to identify patient populations most likely to respond to specific therapies, increasing the probability of clinical trial success. Not financial advice.

How frequently does LTRN data refresh on this page?

LTRN's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven LTRN's recent stock price performance?

Lantern Pharma Inc. (LTRN) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary AI platform (RADR). See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider LTRN overvalued or undervalued right now?

Lantern Pharma Inc. (LTRN) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Can I buy fractional shares of LTRN?

Fractional-share availability for Lantern Pharma Inc. (LTRN) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 14 figures on this page — 7 from Financial Modeling Prep (FMP), 6 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.